| dc.contributor.author | Ermis, Ezgi | |
| dc.contributor.author | Bilir, Ayhan | |
| dc.contributor.author | YAZIHAN, NURAY | |
| dc.contributor.author | Sencan, Mine | |
| dc.contributor.author | Erguven, Mine | |
| dc.date.accessioned | 2021-03-05T07:29:08Z | |
| dc.date.available | 2021-03-05T07:29:08Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | Bilir A., Erguven M., Ermis E., Sencan M., YAZIHAN N., "Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro", JOURNAL OF GYNECOLOGIC ONCOLOGY, cilt.22, ss.225-232, 2011 | |
| dc.identifier.issn | 2005-0380 | |
| dc.identifier.other | av_940d5e8a-5b67-4e2f-808a-9c09fb356bd7 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/99749 | |
| dc.identifier.uri | https://doi.org/10.3802/jgo.2011.22.4.225 | |
| dc.description.abstract | Objective: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies. | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | Cerrahi Tıp Bilimleri | |
| dc.subject | Kadın Hastalıkları ve Doğum | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | KADIN HASTALIKLARI & DOĞUM | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF GYNECOLOGIC ONCOLOGY | |
| dc.contributor.department | İstanbul Yeni Yüzyıl Üniversitesi , , | |
| dc.identifier.volume | 22 | |
| dc.identifier.issue | 4 | |
| dc.identifier.startpage | 225 | |
| dc.identifier.endpage | 232 | |
| dc.contributor.firstauthorID | 202620 | |
